

BLOOD CANCER TIMING EXCEPTIONS

Do not apply one post-treatment clock to every hematologic malignancy.

EVIDENCE PLATE

CLAIM FILE

7709	Hodgkin lymphoma 100 percent during active disease or treatment. Mandatory examination six months after treatment is discontinued.	7715	Non-Hodgkin lymphoma 100 percent during active disease, treatment, or qualifying indolent phase. Mandatory examination two years after treatment ends.
7712	Multiple myeloma Symptomatic disease is 100 percent. Mandatory examination occurs five years after diagnosis under the current code.	7703	Leukemia Use the exact leukemia code and current criteria, including treatment and residual instructions.
RECUR	Recurrence or active disease Document renewed disease activity, treatment, and current hematology assessment.	RESID	Residuals After the applicable transition, rate anemia, neuropathy, organ damage, fatigue, and other supported residuals under appropriate codes.

